publication date: Dec. 21, 2010

In this issue: 

As Amgen, Johnson & Johnson Battle Over Anemia Market, Medicare Enters The Fray;

Texas Oncology Designated Aranesp As Preferred Treatment;

After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk;

Foundation Gives $1 Million To UPCI For Genetics Chair;

Funding Opportunities

(8-page issue).

Download (PDF 376KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.